Evidence map›Paper›PMID 10854037›Full record

ReviewJournal of molecular neuroscience : MN

A new concept in the pharmacology of neuroprotection.

I Gozes, D E Brenneman

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular neuroscience : MN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01056965 (A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01056965 phase1completednot on this map

A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2012Enrolled12ConditionsPredicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration SyndromeArmsdavunetide (AL-108, NAP), Placebo nasal spray
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Peptide receptors as cancer drug targets.Annals of the New York Academy of Sciences · 2019
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Neuroprotective strategies in Alzheimer's disease.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2004
    Review
  20. NAP mechanisms of neuroprotection.Journal of molecular neuroscience : MN · 2004
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 4 countries.

I GozesDepartment of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel. igozes@post.tau.ac.il
D E Brenneman
National Institutes of Health · USTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasoactive intestinal peptide (VIP), originally discovered in the intestine as a peptide of 28 amino acids, was later found to be a major brain peptide having neuroprotective activities. To exert neuroprotective activity, VIP requires glial cells secreting neuroprotective proteins. Activity-dependent neurotrophic factor (ADNF) is a recently isolated factor secreted by glial cells under the action of VIP. This protein, isolated by sequential chromatographic methods, was named activity-dependent neurotrophic factor since it protected neurons from death associated with blockade of electrical activity. A fourteen-amino-acid fragment of ADNF (ADNF-14) and the more potent, nine-amino-acid derivative (ADNF-9), exhibit activity that surpasses that of the parent protein with regard to potency and a broader range of effective concentration. Furthermore, the peptides exhibit protective activity in Alzheimer's disease-related systems (e.g., beta-amyloid toxicity and apolipoprotein E deficiencies, genes that have been associated with Alzheimer's disease onset and progression). ADNP is another glial mediator of VIP-associated neuroprotection. NAP, an eight-amino-acid peptide derived from ADNP (sharing structural and functional similarities with ADNF-9), was identified as the most potent neuroprotectant described to-date in an animal model of apolipoprotein E-deficiency (knock-out mice). These femtomolar-acting peptides form a basis for a new concept in pharmacology: femtomolar neuroprotection.

Indexed as

Neuroprotective AgentsAnimalsApolipoproteins EHumansMiceMice, KnockoutNerve Tissue ProteinsNeurogliaNeuropeptidesOligopeptidesVasoactive Intestinal Peptideactivity-dependent neurotrophic factorApolipoproteins ENerve Tissue ProteinsNeuropeptidesNeuroprotective AgentsOligopeptidesVasoactive Intestinal Peptide

Identifiers

PMID10854037
OpenAlexW2012356006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.